- Home
- NBR vs PVLA Comparison
NBR vs PVLA Comparison
Compare NBR & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBR | PVLA |
|---|---|---|
| Founded | 1952 | 2015 |
| Country | Bermuda | United States |
| Employees | 13900 | 29 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NBR | PVLA |
|---|---|---|
| Price | $86.70 | $112.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | $75.00 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 255.4K | 216.4K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.65 | N/A |
| Revenue Next Year | $4.88 | $104,350.18 |
| P/E Ratio | $4.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.33 | $21.55 |
| 52 Week High | $112.90 | $151.18 |
Technical Indicators
Market Signals| Indicator | NBR | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 37.73 | 49.99 |
| Support Level | $75.43 | $109.68 |
| Resistance Level | $92.38 | $118.23 |
| Average True Range (ATR) | 5.01 | 7.25 |
| MACD | -1.50 | 0.86 |
| Stochastic Oscillator | 15.75 | 65.50 |
Price Performance
Historical ComparisonAbout NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.